Inflammation is thought to play a key role in malignant disease and may play a significant part in the expression of cancer-related symptoms. Cannabidiol (CBD) is a bioactive compound in cannabis and is reported to have significant anti-inflammatory properties.
Serial C-reactive protein (CRP) levels were measured in all participants recruited to a randomised controlled trial of CBD versus placebo in patients with symptoms related to advanced cancer. A panel of inflammatory cytokines was measured over time in a subset of these patients.
There was no difference between the two arms in the trajectory of CRP or cytokine levels from baseline to day 28.
We were unable to demonstrate an anti-inflammatory effect of CBD in cancer patients.
ANZCTR 26180001220257, registered 20/07/2018.